Clinical Trial Matcher

NCT06428006

Efficacy of Cognitive Behavioral Therapy for Insomnia to Treat Insomnia Symptoms in Individuals With Multiple Sclerosis

Recruiting · Phase 2 · University of Kansas Medical Center · registry updated 2026-06-12

Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.

The incidence of insomnia is estimated to be as high as 90% in individuals with MS due to insomnia being underdiagnosed. Sleep disturbances in people with MS have been associated with reduced cognitive performance, physical function, psychological well-being, quality of life, and occupational function, as well as increased prevalence of fatigue, pain, depression, and anxiety. The objective of the proposed study is to determine the efficacy of cognitive behavioral therapy for insomnia (CBT-I) to improve insomnia symptoms (Aim 1) fatigue, and health-related quality of life (Aim 2) in individuals with multiple sclerosis compared to an active control group, and to determine the characteristics of participants that predict improvement in sleep outcomes (Exploratory Aim 3).

Inclusion

  • Diagnosis of relapsing-remitting or secondary progressive MS based on established guidelines20 and verified by their neurologist
  • Mild-to-moderately severe disability (≤ 6 on Patient Determined Disability Steps (PDDS) scale)
  • Report of difficulty falling asleep, maintaining sleep, or waking up too early at least 3 nights/week for the past 3 months with significant distress and impact on function despite adequate opportunity for sleep and not due to other sleep disorders as indicated in the DSM-5
  • ≥10 on Insomnia Severity Index
  • English speaking
  • ≥31 on modified Telephone Interview of Cognitive Status23

Exclusion

  • Known untreated sleep disorder (such as sleep apnea or restless legs syndrome)
  • \>3 on STOP BANG indicating increased risk of sleep apnea
  • Restless legs syndrome as determined by RLS-Diagnosis Index
  • Circadian rhythm sleep-wake disorder as determined by the Sleep Disorders-Revised
  • Parasomnia as determined by the Sleep Disorders-Revised
  • Currently taking benzodiazepines, non-benzodiazepines, or melatonin supplements or agonists for insomnia

Open NCT06428006 on ClinicalTrials.govAll conditions

Efficacy of Cognitive Behavioral Therapy for Insomnia to Treat Insomnia Symptoms in Individuals With Multiple Sclerosis | Clinical Trial Matcher